Cargando…

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis

Recent progress in the treatment of advanced melanoma has led to the improved survival of affected patients. However, novel treatments also lead to considerable and distinct skin toxicity. To further characterize cutaneous adverse events (AE) of systemic treatments, we conducted a single-center retr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kraehenbuehl, Lukas, Schneider, Stephanie, Pawlik, Laura, Mangana, Joanna, Cheng, Phil, Dummer, Reinhard, Meier-Schiesser, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383648/ https://www.ncbi.nlm.nih.gov/pubmed/37513847 http://dx.doi.org/10.3390/ph16070935

Ejemplares similares

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Recent Progress in the Diagnosis and Treatment of Melanoma and Other Skin Cancers
por: Pawlik, Laura, et al.
Publicado: (2023)

What Is New in Cutaneous T Cell Lymphoma?
por: Morgenroth, Sarah, et al.
Publicado: (2023)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2021)

Addendum: Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2022)

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
por: Pham, James P., et al.
Publicado: (2023)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
por: Mangana, Joanna, et al.
Publicado: (2017)

Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement
por: Kuo, Alyce M., et al.
Publicado: (2022)

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma
por: Lear, John T., et al.
Publicado: (2021)

A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis
por: Jenni, D, et al.
Publicado: (2016)

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages
por: Huber, Roman, et al.
Publicado: (2016)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
por: Nikolaou, Vasiliki, et al.
Publicado: (2023)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
por: Shahin, Ahmad, et al.
Publicado: (2022)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
por: Burzi, Lorenza, et al.
Publicado: (2021)

SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma
por: Pópulo, Helena, et al.
Publicado: (2017)

The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2017)

Vemurafenib and cutaneous adverse events - report of five cases
por: Silva, Giselle de Barros, et al.
Publicado: (2015)

Cutaneous Adverse Events After COVID-19 Vaccination
por: Weschawalit, Sinee, et al.
Publicado: (2023)

Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [(18)F]FDG PET/CT
por: Liberini, Virginia, et al.
Publicado: (2021)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2a41vror64pdjoch9tqlq34ttr